Potentiation of the L-Dopa effect in man by the use of catechol-O-methyltransferase inhibitors.

作者信息

Ericsson A D

出版信息

J Neurol Sci. 1971 Oct;14(2):193-7. doi: 10.1016/0022-510x(71)90088-8.

DOI:10.1016/0022-510x(71)90088-8

PMID:5112212

Abstract

摘要

相似文献

Potentiation of the L-Dopa effect in man by the use of catechol-O-methyltransferase inhibitors.

J Neurol Sci. 1971 Oct;14(2):193-7. doi: 10.1016/0022-510x(71)90088-8.

Sensitivity studies of L-dopa metabolites in reserpinized rats and their clinical significance.

Neurology. 1971 Nov;21(11):1129-33. doi: 10.1212/wnl.21.11.1129.

Levodopa in Parkinsonism.

Drugs. 1971;2(4):257-61. doi: 10.2165/00003495-197102040-00001.

L-dopa in senile dementia.

Lancet. 1970 Mar 14;1(7646):573-4. doi: 10.1016/s0140-6736(70)90819-6.

L-dopa. II.

Br Med J. 1970 Nov 28;4(5734):541-2.

[Problems and therapy of L-DOPA-induced dyskinesias].

Nervenarzt. 1972 Nov;43(11):584-6.

[Abnormal movements induced by L-Dopa and dopamine metabolism disorders].

Rev Neurol (Paris). 1973 Dec;129(6):313-24.

[Treatment of Parkinson's disease with L-dopa combined with a decarboxylase inhibitor].

Dtsch Med Wochenschr. 1969 Dec 26;94(52):2678-81. doi: 10.1055/s-0028-1110503.

Attempted use of haloperidol in the treatment of L-dopa induced dyskinesias.

J Neurol Neurosurg Psychiatry. 1974 Apr;37(4):427-30. doi: 10.1136/jnnp.37.4.427.

[Abnormal movements observed during treatment of Parkinson's disease with L-dopa].

Rev Neurol (Paris). 1970 Feb;122(2):103-12.

引用本文的文献

L-DOPA-therapy in Parkinson's disease: some personal reflections on L-DOPA therapy from Vienna and Berlin.

J Neural Transm (Vienna). 2023 Nov;130(11):1323-1335. doi: 10.1007/s00702-023-02692-9. Epub 2023 Oct 5.

Discovery and characterization of naturally occurring potent inhibitors of catechol--methyltransferase from herbal medicines.

RSC Adv. 2021 Mar 11;11(17):10385-10392. doi: 10.1039/d0ra10425f. eCollection 2021 Mar 5.

Acute administration of L-DOPA induces changes in methylation metabolites, reduced protein phosphatase 2A methylation, and hyperphosphorylation of Tau protein in mouse brain.

J Neurosci. 2012 Jul 4;32(27):9173-81. doi: 10.1523/JNEUROSCI.0125-12.2012.

Catechol-O-methyltransferase and its inhibitors in Parkinson's disease.

CNS Drug Rev. 2007 Fall;13(3):352-79. doi: 10.1111/j.1527-3458.2007.00020.x.

Treatment of cognitive deficits associated with schizophrenia: potential role of catechol-O-methyltransferase inhibitors.

CNS Drugs. 2007;21(7):535-57. doi: 10.2165/00023210-200721070-00002.

Diagnosis and treatment of Parkinson disease: molecules to medicine.

J Clin Invest. 2006 Jul;116(7):1744-54. doi: 10.1172/JCI29178.

Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson's disease.

Drugs. 2000 Jun;59(6):1233-50. doi: 10.2165/00003495-200059060-00004.

Effect of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, on the motor response to acute treatment with levodopa in patients with Parkinson's disease.

J Neurol Neurosurg Psychiatry. 1994 Feb;57(2):186-9. doi: 10.1136/jnnp.57.2.186.

Catechol-O-methyltransferase inhibition by U-0521 increases striatal utilization of levodopa.

Naunyn Schmiedebergs Arch Pharmacol. 1982 Jul;320(1):34-7. doi: 10.1007/BF00499068.

Anti-parkinsonian drugs today.

Drugs. 1984 Sep;28(3):236-62. doi: 10.2165/00003495-198428030-00002.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验